UFL adds Mike Repole as an owner — and he's eyeing 16 teams by 2035
Despite disappointing metrics in its second season after the USFL/XFL merger, it has attracted another major investor. And he has big plans.
Mike Repole, who cofounded vitaminwater, smartwater, and BodyArmor before selling them to Coca-Cola for more than $12 billion, joins RedBird Capital Partners, FOX, ESPN, Dany Garcia, and Dwayne Johnson as owners of the league.
'Football has clearly established itself as America's most popular sport, with tremendous momentum and demand,' Repole said in the press release announcing the development. 'There's no better time than now to build a strong, sustainable spring league that unites players, teams, and fans. I'm honored to join the United Football League's ownership group as we work to create something truly lasting and game-changing.'
The initial changes to the game reportedly include the relocation of half of the league, with Birmingham, Michigan, Houston, and Memphis franchises heading to new markets. In an interview with Kevin Seifert of ESPN.com, Repole confirmed that at least two and as many as four teams will move for 2026.
Repole also said that one of the new markets will be Columbus, with the UFL team playing at the MLS stadium built for the Columbus Crew.
He wants venues that feel alive. Which makes smaller stadiums critical.
"The vibe hasn't been to where it should be," Repole said. "You can hear a pin drop when someone runs 80 yards. That's not so good. Nobody wants to turn on the TV and see 10,000 fans in a 65,000-seat stadium. It's like watching a COVID game."
As the facilities shrink, the teams could grow. Repole wants to double the size of the UFL, within the next decade.
"We're going to be aggressive as far as being nimble and scrappy and gritty and making aggressive moves," Repole said. "If by 2035, if we can't have 16 teams, I'm going to consider it a personal failure. This is it. Other leagues didn't have the capital that this league has, didn't have the media giants that this league has, didn't have the entrepreneurs that this team has."
He's right about that. The key will be to create an appetite for football when it's not football season. That's the fundamental challenge that all spring or summer leagues have faced.
Which means that the best way to succeed as an alternative league would be to play games during NFL season, on the days when the NFL isn't playing games: Tuesday, Wednesday, Saturday, Sunday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Top of the Morning: Red Sox beat sloppy Astros 6-1 behind Lucas Giolito's stellar start
BOSTON (AP) — Trevor Story and Ceddanne Rafaela had consecutive RBI singles in a six-run fourth inning filled with five Houston mistakes, Lucas Giolito pitched a season-high eight stellar innings, and the Boston Red Sox beat the Astros 6-1 on Sunday to complete a series sweep. Connor Wong added a sacrifice fly and Wilyer Abreu was credited with a sacrifice on a safety squeeze for an RBI during the inning, sending Boston to its third straight win over the AL West leaders and fifth in a row overall. Giolito (8-2) gave up the run on three hits with four strikeouts and a walk, eclipsing his previous season-high innings of 7 2/3 on July 4. Carlos Correa, acquired from Minnesota at the trade deadline, hit a homer for Houston, which has lost eight of 10. The game's first pitch was 11:38 a.m. EDT, the third time this season the Red Sox began a game in the morning. The others: their annual Patriots' Day game when they beat the White Sox and the Independence Day victory at the Nationals. Framber Valdez (11-5) gave up six runs, four earned, over six innings, ending his personal 10-game winning streak. He entered 10-0 with a 1.84 ERA in his previous 14 starts. Key moment During the fourth, Houston missed a cutoff on Story's run-scoring single, Valdez had a wild pitch, balked home a run and had Abreu's bunt go under his glove for an error. Yainer Diaz had a passed ball. Key stat Valdez hadn't allowed three runs in an inning since May 19. Up next Astros: RHP Jason Alexander (1-1, 7.36 ERA) is slated to start the opener of a three-game series at the Marlins on Monday. Red Sox: RHP Brayan Bello (7-5, 3.19) is set to start the first of three against the Royals on Monday. ___ AP MLB: ___ This story has been corrected to show that the Red Sox have won five consecutive games, not four. Ken Powtak, The Associated Press
Yahoo
25 minutes ago
- Yahoo
Steel Dynamics, Inc. (STLD): A Bull Case Theory
We came across a bullish thesis on Steel Dynamics, Inc. on Stock Picker's Journey's Substack by Gregg Jahnke. In this article, we will summarize the bulls' thesis on STLD. Steel Dynamics, Inc. 's share was trading at $127.56 as of July 31st. STLD's trailing and forward P/E were 18.51 and 14.29 respectively according to Yahoo Finance. Steel Dynamics (STLD) has been added to the Model 25 portfolio at $131, replacing AES, in a rare top-down decision driven by macroeconomic expectations rather than valuation. While the author typically favors bottom-up stock picks like Pepsi and Gentex, which were purchased at near-decade lows, the potential passage of the BBBill and a possible economic surge in 2026 prompted this more thematic move. STLD stands to benefit from pro-growth industrial policies, and with momentum shifting in favor of the bill's passage, exposure to a high-quality cyclical stock became desirable. A standout first-quarter earnings call reinforced conviction, as STLD's aggressive capital expenditure plans—particularly its efforts to reshape the aluminum industry—signal long-term vision. Notably, the company has repurchased 40% of its stock over the past decade and maintains a clean balance sheet, having recently refinanced debt with manageable near-term maturities. Although other aluminum plays like Century, Alcoa, and Kaiser were considered, STLD was viewed as superior, even compared to Nucor (NUE), due to its aluminum exposure. Wall Street's focus on short-term earnings has led to a misunderstanding of STLD's strategic positioning, as highlighted by analyst John Tumazos's incisive questioning on the Q1 call. The company's spread-based model in scrap steel and aluminum is seen as lower risk than perceived, with significant upside potential. Strong institutional support from Victory Capital, Norges Bank, and T. Rowe Price adds credibility to the investment. Though STLD has underperformed recently and issued a soft Q2 outlook, the long-term case for its role in rebuilding U.S. manufacturing justifies the timing of this buy. Previously, we covered a on Steel Dynamics, Inc. (STLD) by Gregg Jahnke in February 2025, which highlighted the company's capital discipline, low-cost structure, and long-term potential. The company's stock price has depreciated approximately by 4% since our coverage due to near-term macro headwinds. Gregg Jahnke shares a similar view but emphasizes a top-down, policy-driven case based on expected 2026 growth. Steel Dynamics, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held STLD at the end of the first quarter which was 45 in the previous quarter. While we acknowledge the potential of STLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
